key: cord-0767591-j9edc92s
authors: Oliani, Francesco; Savoia, Antonella; Gallo, Giulia; Tiwana, Navpreet; Letzgus, Matteo; Gentiloni, Flaminia; Piatti, Alessandra; Chiappa, Laura; Bisesti, Alberto; Laquintana, Dario; Castaldi, Silvana
title: Italy’s rollout of COVID-19 vaccinations: the crucial contribution of the first experimental mass vaccination site in Lombardy
date: 2022-02-03
journal: Vaccine
DOI: 10.1016/j.vaccine.2022.01.059
sha: ab964794df4382939f793fb516a608b7669aa4f5
doc_id: 767591
cord_uid: j9edc92s

BACKGROUND: In occurrence of the coronavirus disease 19 (COVID-19) pandemic, carrying out an efficient large-scale vaccination campaign is vital in order to control the virus. Especially in high prevalence areas of COVID – 19, it is crucial to implement an effective vaccination strategy. In Italy, programming an efficient COVID-19 mass vaccination campaign has been the main target of the Ministry of Health. AIMS: This paper gives a comprehensive overview of how the mass vaccination campaign is performed in Milan, one of the cities that has been mostly affected by the COVID-19 pandemic in Italy. We analyze the vaccination strategy implemented by Fondazione Ca’ Granda – Ospedale Maggiore Policlinico located in Milan. Furthermore, we compare the organization of this campaign in regards of those carried out across EU and UK. MATERIALS AND METHODS: The data derive from an analysis of the different vaccination plans implemented across EU and UK from the 27/12/2020 to the 15/06/2020. In addition, we discuss the data collected from the internal data server of IRCCS Fondazione Ca’ Granda – Ospedale Maggiore Policlinico from the 15/02/2021 to the 15/06/2021.The collected data are examined by means of descriptive statistics. RESULTS: From the analysis of the internal data server, we observe that the modular organization of Fiera Milano City guarantees up to 5000 vaccinations/day. Moreover, the precise flow organization of users and a series of strategies adopted to avoid identification errors or vaccine type administration errors are crucial to reach the aforementioned target. CONCLUSIONS: The institution of mass vaccination centers thanks to the optimization of all the involved processes and the meticulous organization of these structures, allows to avoid crowds and guarantees the administration of elevated amounts of vaccines. All these elements assure a rapid vaccination coverage of the population in Lombardy, with a meaningful increase in daily administration doses.

On March 11, 2020, the World Health Organization (WHO) declared the spread of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be a pandemic. 1 Since then, great technological and scientific efforts have been made to allow the development and distribution of safe and effectiveness vaccines against coronavirus disease . Never before had a vaccine been developed in such a short time span. In addition, in order to achieve as soon as possible an appropriate vaccine coverage those new vaccines need to be distributed as rapidly as possible.

Therefore, organizing a mass vaccination campaign on a global scale is a priority to contain the spread of the virus and allow a gradual resumption of economic and social activities. The purpose of this article is to compare different organizational and management models of vaccination campaigns of some European and non-EU Countries, focusing on the model proposed by the IRCCS-Ca 'Granda Fondazione which has become the first mass vaccination center in Lombardy.

The IRCCS-Ca 'Granda Fondazione (Fondazione) is the first public hospital for research and scientific productivity in Italy as well as the reference hospital for the city of Milan. As well-known Milan, the capital city of Lombardy region is the most affected area in Italy since the beginning of the COVID-19 pandemic. Given the central location of Fondazione in the city of Milan, the organization of the vaccination center had to overcome both logistical and structural problems in order to be able to ensure adequate volumes of administration.

At this time, two types of vaccine have been approved and marketed: an mRNA and a viral vector; the first phase of the massive vaccination campaign was based exclusively on the administration of mRNA vaccines. 2, 3 Later, thanks to the approval of viral vector vaccines, it has been possible to expand the vaccine offer and to allow a more rapid progression of the vaccination campaign.

All data from different EU Countries were collected from official website of European Center of Disease Control (ECDC), a literature review has been conducted using PubMed, Scopus and Web of Science, without language restrictions. We restricted the research to articles that included the words "vaccination", "vaccine", "rollout" "mass vaccination" and "COVID-19 vaccination" in their titles or abstracts. We furthered searched reference lists of identified publications for citations of additional relevant articles. Fondazione data were obtained by internal database.

UK has been the first Country in the world to begin the distribution and administration of the SARS-COV2 vaccines on 08/12/2020, followed by USA on 14/12/2020, Israel on 20/12/2020. Meanwhile EU Countries began the distribution and administration of vaccines on 27/12/2020. 2,3 Since the beginning of the vaccination campaign, Israel has been the leading nation in terms of doses administered per 100 people. At this time around 59% of the Israelis population has completed the vaccination cycle. 4 The great success of the Israelis vaccination campaign was achieved thanks to a mixture of longstanding characteristics both extrinsic and intrinsic to the Israeli healthcare service.

The first strongpoint to highlight is Israel small size in terms of area and population and the relatively young population. Another important characteristic is the centralized national system of government associated with Israel's experience in implementing large scale responses in case of national emergencies. 5, 6 On the other hand, the most important players that contributed to the campaign success are the organization, logistics and coordination of the four healthcare plans. In fact, these health plans are efficiently coordinated with hospitals, the government and emergency care providers.

Moreover, the availability of a preexisting well-functioning framework allowed a fast decision making and mobilization of the resources in order to support the campaign. Another crucial effort to speed up the vaccination process was to acquire a large amount of vaccine compared to the population size and to clearly and easily identify priority criteria at the beginning of the distribution process. Last but not least it is important to point out the creative measures adopted in order to meet the storage requirement as well as to encourage the population to sign up for the vaccination. 7 Meanwhile in USA 42% of the overall population have already completed the vaccination cycle. 4 A peculiar characteristic of the American vaccine campaign is the lack of priority groups. Nevertheless, the strongest point of the USA campaign is the availability of the largest amount of COVID-19 vaccine, as it is the manufacturing Country of the two mRNA vaccines currently marketed as well as the Johnson & Johnson viral vector vaccine. 8 Similarly in UK the amount of people that completed the 2 doses vaccination cycle with either an mRNA vaccine or Vaxzevria is 42% corresponding to around 29 million in a population of 65.637.239 in total. 4 As previously stated, UK became the first Country in the world to approve a COVID-19 vaccine for emergency use early in December. Nevertheless, the groundwork was laid nearly a year earlier, when the Department of Health and Social Care reportedly began planning a mass vaccination program, in January 2020, before first COVID-19 case in the UK was confirmed. 9 At the time, they were already working on a prototype vaccine against the coronavirus that causes Middle East Respiratory Syndrome (MERS) and reasoned that they would be able to adapt the chimpanzee adenovirus vector they were using to confer protection against the SARS-CoV-2.

Moreover, another important strategical aspect that contributed to UK success in the vaccination effort was its promptness to strike a deal on vaccine deliveries batches three months before the EU's.

As a result of this, UK's batches were set in motion earlier and separate to those earmarked for the EU. 10 On the other hand, despite a target value of 70 doses per 100 people EU has currently administered an average of 50 doses per 100 people. At the same time, the number of people that completed the 2 doses vaccination cycle are around 25.8%. 11 EU Countries autonomously organized the vaccination campaign following the guidelines of their own Minister of Health. Across EU Countries we can identify different organizational models, but with similar characteristics. A common aspect of the various organizational models is undoubtedly the introduction of priority groups, defined as clusters of the population to whom the vaccine should firstly be administered. Each Country identified different phases in which different population clusters converge. Ideally at the end of each phase the following phase opens. 12,13

Comparing Italian data with the European ones available through the ECDC website, Italy is currently in line with the vaccination trend across all Europe. In order to maximize the result, the strategical decision was to focus the use of the limited resources available on protecting personnel dedicated to pandemic emergency and on the most fragile subjects (health and social health workers, the staff and guests of residential facilities for the elderly). Thanks to the increase in the availability of vaccines the vaccination process started to be carried out also on other risk categories and then on the rest of the general population. 12,13 Aspects correlated to procurement and logistics are the responsibility of the Extraordinary Commissioner.

Vaccines requiring storage at temperatures of -20 ° / -70 ° are delivered directly by the manufacturing companies in 300 sites appropriately identified by the Regions. On the other hand, vaccines that can be stored at the so-called "standard cold" temperatures (+ 2 / + 8 ° C) are distributed according to the "hub and spoke" model (a national storage and delivery center following the second level territorial centers). 17 According to what was communicated by the Ministry of Health, the agreements provide for the arrival of 469,950 weekly doses in Italy, as of 1 May 2021 over 20,000,000 single doses of vaccine were administered. 15, 16 At the time of writing the age group with the highest vaccine coverage is represented by the over 80 population. In fact, over 94% of this cohort group has already received the first dose. As far as the other age groups are concerned, the vaccination coverage is lower.

In Italy, the leading region in terms of vaccine doses administered is Molise with 71 doses per 100 people (20.61% of the population has completed the vaccination cycle). On the other hand, the region that has administered the smallest number of doses is Sicily, (Figure 1 ), with around 61 doses per 100 people (around 19% of the population have completed the vaccination cycle). According to the number of doses administered in the population, Lombardy region is found at the fourth position. In greater detail we see that around 70 doses have been administer every 100 people and 21.31% of the population has completed the vaccination cycle. 14 At the time of writing Lombardy region has surpassed the record of 7 million doses administered, corresponding to 92% of the doses received by the manufactures. The region aims at 9 million vaccinated by July with a daily average of 120,000 administrations. At the beginning of the vaccination campaign, the region suffered delays mainly due to the lower availability of vaccine doses and the lack of dedicated staff. Subsequently, thanks to the increased availability of vaccine doses but especially thanks to the construction of mass vaccination centers, Lombardy region continued the vaccination campaign at a faster pace. As a matter of fact, the number of daily doses administered has gone up from about 6000 to about 90000 in Lombardy. According to the plans of Lombardy region, the booking round for the Lombards will be completed by early June. Finally, even those over 16 will be able to access reservations. Therefore, given the latest development it can be considered a successful vaccination campaign. In addition, whether Lombardy reaches the goal of vaccinating all Lombards with at least one dose by 30 August will only depend on the arrival of the new vaccines. Focusing on IRCCS Fondazione Ca' Granda -Policlinico Ospedale Maggiore vaccine administration (Table 1) 

In Fiera Milano City MVC vaccine administration is managed through four different process lines: Another interesting aspect which has been highlighted from this optimization and simulation process is the importance of monitoring the arrival rate of people. According to this model the arrival rate should be set at a maximum of 86 people/15 minutes in order to guarantee an acceptable waiting time to avoid crowds. This experimentation has laid the foundations of the MVC model that is now adopted in all Lombardy. 19 

On 6 th and 7 th February 2500 AREU volunteers completed their vaccine cycle with their second dose.

As seen in the previous paragraph this was an operating simulation to optimize and calculate the timing of the vaccination process since entering the Fiera Pavilion to the inoculation of the vaccine, as well as to highlight the critical issues and planning the opening to the rest of the population.

During the early stages of the vaccination campaign in the vaccination centers there was only one type of vaccine. This has inevitably led to the presence of ineligible candidates for that specific vaccine not to be vaccinated that day. This critical point has been overcome since different types of vaccines have now been made available in the center. This last point is one of the positive aspects of massive vaccination centers in which multiple vaccine types are available.

On the other hand, vaccine management has become even more complicated since the simultaneous administration of first and second doses of different vaccines has begun.

In order to reach an appropriate result in terms of the amount of vaccine administered, it is crucial to take into account both the critical issues that may derive from the vaccination process and the relative measures taken to cope with them.

First of all, the high personnel turnover requires a learning system which promptly adopts and embraces the Ministry of Health and AIFA notes. To avoid crowds correlated to personnel training, supervisors adopted several strategies such as organizing online meetings with videocall platforms and distance learning tests, regular email sending of informative material with the Ministry and AIFA latest provisions concerning vaccine administrations. After completing an initial phase of distance learning, a support and training phase with more experienced staff was organized. Personnel follow operative instructions contained in a manual, continuously updated and easy to understand.

Another criticism is the slowdown of the administration process due, for example, to increasing people flow in a module from reception area to anamnestic area and then to administration boxes: different modules may have a different process speed in each of their area. To solve this critical point, volunteers could address people to modules less congested without blocking the whole MVC.

Authorities' directives are rapidly changing, and this requires the adoption of coping measures to avoid the error of administration. The first action taken to achieve this goal is to perform a first screening in the reception area in order to discriminate if the user requires a first or second dose of the vaccine. Up to now, it is not allowed to mix different vaccine types in a vaccination cycle. Once the anamnesis ends, a second check point is established to avoid that people enter the wrong administration box: medical doctors or volunteers hand over a jacket or a colored sheet to mRNA vaccination users. Another point that needs attention is the age of the user: each age group requires a specific vaccine type approved by EMA and AIFA and it is mandatory for doctors to know user's age. In order to avoid mistakes the medical and nursing staff repeatedly check the coherence among the vaccine administered and the user's age. In case an error occurs, the staff is asked to put down a report to analyze how the error occurred and how to avoid repeating it in the future.

Finally, allergies can be another critical issue important to take into account. In fact, sometimes users can't be vaccinated in their reservation days because of pre-existing severe allergic reactions that require an allergic evaluation from specialists. This incident could delay the administration of the first vaccine dose and expose the allergic user to COVID-19 infection. In addition, an allergic reaction occurring after the first dose it may lead to exceed the given time limit between two doses. In Fiera Milano City a priority line was organized for people who require a novel reservation. Allergic subjects may be evaluated in Fondazione to decide whether they are eligible to be vaccinated. In addition those requiring it may have their vaccine administered in a secure environment in the intensive care unit in Fondazione.

The 

Director-General's opening remarks at the media briefing on COVID-19 -11

Evidence-based support for the allhazards approach to emergency preparedness

On constant alert: lessons to be learned from Israel's emergency response to mass-casualty terrorism incidents

Israel 's rapid rollout of vaccinations for

CDC. Different COVID-19 Vaccines

COVID-19: rejected contracts and a Hollywood movie-how UK struck deal to guarantee vaccine supply.No Title. Sky News

COVID-19 : How the UK vaccine rollout delivered success, so far

Overview of the implementation of COVID-19 vaccination strategies and vaccine

Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU / EEA Key findings

Gedi Visual. Coronavirus, le vaccinazioni in Italia regione per regione

Ministero della salute, Presidenza del Consiglio dei Ministri, Commissario Straordinario COVID-19

Commissario Straordinario COVID-19

Raccomandazioni per l'organizzazione della campagna vaccinale contro SARS-CoV-2/COVID-19 e procedure di vaccinazione

COVID-19 CS per l'attuazione e il coordinamento delle misure sanitarie di contenimento e contrasto dell'emergenza epidemiologica

Regione Lombardia Realizzazione polo vaccinale massivo

Conceptualization, Writing -original draft, Visualization, Writingreview & editing. Antonella Savoia: Conceptualization, Writing -original draft, Visualization, Writing -review & editing. Giulia Gallo: Conceptualization, Writingoriginal draft, Visualization, Writing -review & editing. Navpreet Tiwana: Conceptualization, Data Curation, Resources. Matteo Letzgus: Conceptualization, Data Curation, Resources. Laura Chiappa: Conceptualization, Resources Alessandra Piatti: Conceptualization, Data Curation, Resources Flaminia Gentiloni: Data Curation, Resources Alberto Bisesti: Resources, Data Curation Dario Laquintana: Resources, Data curation. Silvana Castaldi: Conceptualization, Methodology, Supervision, Writing -review and editing

All Authors declare to have not conflict of interests.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

 Different vaccination plans across EU and non-EU Countries, with their own peculiarities  Italian vaccine campaign: priority groups and national guide lines for vaccine rollout  Fiera Milano Pavilion is the first experimental mass vaccination site in Lombardy